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Recent Development
Metabolite Labs and Patentable Subject Matter: A Review of
Federal Circuit and PTO Precedent was Narrowly Averted,
but for How Long?
Michelle E. Dawson ∗
One cannot patent “laws of nature, natural phenomena,
and abstract ideas.” 1 On October 31, 2005, the United States
Supreme Court granted certiorari, in the case of Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc., to determine whether
claim thirteen of Competitive Technologies, Inc.’s (CTI) U.S.
Patent No. 4,940,658 (“the ‘658 patent”) was invalid because it
recited nothing more than a natural phenomenon. 2 On June
22, 2006, after hearing oral arguments, the Court dismissed the
writ as “improvidently granted”. 3 Despite ultimate dismissal of
the writ, the question remains whether the Federal Circuit and
the United States Patent and Trademark Office’s (PTO)
interpretation of Supreme Court precedent and 35 U.S.C. § 101
on subject matter patentability will be reexamined and possibly
limited or altered by the Supreme Court in the near future.
PATENTABLE SUBJECT MATTER
Section 101 identifies what subject matter may be entitled
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1. Diamond v. Diehr, 450 U.S. 175, 185 (1981).
2. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. 543 (2005)
(granting the petition for writ of certiorari).
3. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. 2921, 2921
(2006) (dismissing the writ of certiorari as improvidently granted).
∗
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to a patent. 4 In Diamond v. Diehr, the leading case on
patentable subject matter and the last case on this topic the
Supreme Court has decided, the Court recognized that
“Congress intended statutory subject matter to ‘include
anything under the sun that is made by man.’” 5 The Court,
however, also reiterated its long-standing determination that
despite the broad scope of patentable subject matter “laws of
nature, natural phenomena, and abstract ideas” are not
patentable, but rather free for all to use. 6 Therefore, as is often
noted, Newton could not have patented the law of gravity and
Einstein could not have patented E = mc². 7 Drawing clear
distinctions between what constitutes permissible subject
matter considered broadly, as Congress intended, and what
constitutes impermissible subject matter because the claim
involves a natural law, natural phenomenon, or abstract idea
has proven challenging for the Court. 8 Despite the difficulty

4. 35 U.S.C.A. § 101 (2006). “Whoever invents or discovers any new and
useful process, machine, manufacture, or composition of matter, or any new
and useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title.” Id.
5. Diehr, 450 U.S. at 182 (quoting S. Rep. No. 82-1979, at 5 (1952), as
reprinted in 1952 U.S.C.C.A.N. 2394, 2399).
6. Id. at 185.
7. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
8. O’Reilly v. Morse, 56 U.S. 62 (1853) (holding Morse’s claim eight
invalid as too broad because it attempted to claim any machinery that used
electromagnetism for making or printing intelligible characters, signs, or
letters, at any distance. The claim was too broad because it precluded others
from using any process or machine, including ones that Morse had not
invented or described, to accomplish the result. Further, the claim was too
broad because Morse had not discovered that the form of machinery did not
matter because electric current would always print at a distance). C.f. Dolbear
v. Am. Bell Tel. Co., 126 U.S. 1 (1887) (finding claim five valid and
distinguishing it from claim eight in Morse because Bell only claimed the
transmission of vocal sounds by means of undulations in continuous current.
Further, the Court noted that at the time, for all anyone knew, that change in
current was required for the current to serve as a medium for speech
transmission. Because Bell was the first to discover how to change the current,
and he claimed changing the current in the way described in the claim to
transmit sound, he was entitled to the patent.). Gottschalk v. Benson, 409 U.S.
63 (1972) (holding a method for converting binary coded decimal numerals into
pure binary numerals unpatentable subject matter because it was merely a
mathematical formula without practical application except in connection with
a digital computer.). Parker v. Flook, 437 U.S. 584 (1978) (holding the claim at
issue, which recited a new method for calculating alarm limit values, invalid
because the only novel thing in the method was the mathematical formula or
algorithm, and was therefore not patentable subject matter). Diehr, 450 U.S.
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the Court has had in determining when to apply the judicial
exceptions to § 101, the standard for meeting the requirement
of § 101 is quite low, and the issue is rarely litigated. 9
THE CASE
Researchers at University Patents Inc. (UPI) discovered a
relationship between an elevated level of total homocysteine
and a deficiency in B vitamins, specifically B12 (cobalamin) and
folic acid (folate). 10 Serious health risks, including vascular
disease, cognitive dysfunction, birth defects and cancer, can
result from a deficiency in these vitamins. 11 If, however, the
deficiency is caught early enough, vitamin supplements can
easily treat the deficiency. 12 UPI inventors developed a method
of assaying for total homocysteine along with other metabolites
that could indicate which vitamin may be deficient. 13 In
general, the ‘658 patent was directed to the developed
diagnostic method for determining whether deficiencies in B12
and folic acid existed. 14 Independent claim thirteen, the sole
claim at issue in the case, recited:
“A method for detecting a deficiency of cobalamin or folate
in warm-blooded animals comprising the steps of: assaying a
body fluid for an elevated level of total homocysteine; and
correlating an elevated level of total homocysteine in said body
fluid with a deficiency of cobalamin or folate.” 15
CTI, UPI’s successor, acquired the rights to the patent
before it issued. 16 CTI granted a non-exclusive license to the
patent to Metabolite Laboratories, Inc. (Metabolite). 17 Under
at 175-76 (holding that while a mathematical formula by itself is not
patentable subject matter, if a claim containing a mathematical formula
implements it in a process that when considered as a whole performs a useful
function, the claim is then patentable. Further the Court found that it was
irrelevant if each step in a process was itself unpatentable, if the process
taken as a whole constituted patentable subject matter).
9. PRATISING LAW INSTITUTE, Overview of Patent Litigation, 798 PLI/PAT
281, 325 (2004).
10. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354,
1358 (Fed. Cir. 2004).
11. Id.
12. Id.
13. Id.
14. U.S. Patent No. 4,940,658 (filed Nov. 20, 1986).
15. Metabolite, 370 F.3d at 1358–59.
16. Brief for Petitioner at 6, Lab. Corp. of Am. Holdings v. Metabolite
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL 3543099.
17. Id.
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the licensing agreement Metabolite was permitted to sublicense the patent to other parties, which Metabolite did. 18
Metabolite sublicensed the patent to Laboratory Corporation of
America Holdings (LabCorp, formerly Roche Biomedical
Laboratories). 19 In 1992, LabCorp began using the assaying
method covered by the ‘658 patent and paying the required
royalties to Metabolite. 20 In 1998, however, LabCorp also
began using a method developed by Abbott Laboratories
(Abbott) for testing for homocysteine alone (without the other
metabolites), which was useful in diagnosing heart disease. 21
LabCorp continued to pay royalties to Metabolite whenever it
used the assaying method claimed in the ‘658 patent, but
LabCorp did not pay royalties when it used the Abbott test. 22
In May 1999, CTI, the patent holder, sued LabCorp for
infringement, inducing infringement and contributory
infringement of claim thirteen. 23 Metabolite sued LabCorp for
breach of the licensing agreement, 24 arguing that the
agreement only permitted LabCorp to use other methods for
assaying for homocysteine levels if the other tests did not
infringe any valid claim of the ‘658 patent. 25 The district court
granted LabCorp’s summary judgment motion on direct
infringement because LabCorp itself did not perform the
correlating step required by claim thirteen. 26 The contributory
infringement charge remained, however, because LabCorp
allegedly induced physicians to infringe claim thirteen
whenever physicians viewed total homocysteine test results
and concluded the patient either did or did not have a vitamin
deficiency. 27 The jury found claim thirteen valid and also

18. Id.
19. Id. at 7. LabCorp is a large clinical reference laboratory that conducts
tests ordered by health care professionals used in diagnosing and treating
patients. Id. at 6.
20. Id. at 7.
21. Metabolite, 370 F.3d at 1359; see also Brief for Petitioner, supra note
16, at 8. The correlation between elevated levels of homocysteine and an
elevated risk of heart disease had been known since 1969 or earlier. Id.
22. Brief for Petitioner, supra note 16, at 9.
23. Brief for Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2006 WL 303905.
24. Id. at 8.
25. Brief for Petitioner, supra note 16, at 7.
26. Id.
27. See Metabolite, 370 F.3d at 1364.
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found that LabCorp willfully induced infringement of the
claim. 28 LabCorp was ordered to pay nearly $5.7 million in
damages. 29 LabCorp’s motion for judgment as a matter of law
was denied and the district court enjoined LabCorp from using
the Abbott test. 30 LabCorp appealed. 31 On appeal, the Federal
Circuit affirmed the district court’s ruling. 32
LabCorp petitioned the Supreme Court of the United
States for writ of certiorari. 33 The Court granted cert only as to
question three of Petitioner’s Petition for Writ of Certiorari: 34
Whether a method patent setting forth an indefinite, undescribed,
and non-enabling step directing a party simply to ‘correlate’ test
results can validly claim a monopoly over a basic scientific
relationship used in medical treatment such that any doctor
necessarily infringes the patent merely by thinking about the
relationship after looking at a test result. 35

After the parties filed their briefs, the Court invited the
Solicitor General, on behalf of the government, to express its
views on whether the patent was invalid because one cannot
patent laws of nature, natural phenomena, and abstract
ideas. 36
After hearing oral arguments on the case from the parties,
as well as the Solicitor General, the Court dismissed the writ as
improvidently granted on June 22, 2006. 37 Justice Breyer,
joined by Justices Stevens and Souter, wrote a vehement
dissent. 38
THE DISMISSAL
While the Court did not provide a reason for dismissing the
writ as improvidently granted, it is likely that the Court was

28. Id. at 1359.
29. Id.
30. Id.
31. Id.
32. Id. at 1372.
33. Petition for Writ of Certiorari at *i, Lab. Corp. of Am. Holdings v.
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2004 WL 2505526.
34. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. at 543.
35. Petition for a Writ of Certiorari, supra note 33, at *i.
36. Brief for United States as Amicus Curiae, Lab. Corp. of Am. Holdings
v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL
3533248.
37. Lab. Corp of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. at
2921.
38. Id.
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heavily influenced by the arguments made in the briefs of the
Respondent (collectively Metabolite), and the Solicitor General,
which strenuously requested that the Court dismiss the writ on
procedural grounds. 39 They argued that the writ was granted
to decide a question which was never addressed in either of the
lower courts, namely § 101 subject matter patentability. 40
LabCorp never specifically cited § 101 in its briefs or oral
arguments in the lower courts, nor did it ever state that claim
thirteen covered unpatentable subject matter. 41 The jury was
not instructed to reach a verdict on whether claim thirteen
recited patentable subject matter. 42 The Federal Circuit did
not consider whether claim thirteen recited patentable subject
matter. 43 In Metabolite’s Supreme Court brief it recited a
panoply of authority from the Federal Rules of Civil Procedure,
to the Patent Act, to the Supreme Court’s own precedent in
order to demonstrate the inappropriateness of reviewing an
issue which was not pleaded, argued, or considered in the lower
courts. 44
The Solicitor General, in its requested brief, also vigorously
argued that the validity of claim thirteen under § 101 should
not be considered by the Court because the issue was “neither
pressed nor passed upon below.” 45 Specifically, the Solicitor
General argued that failure to bring up a § 101 defense
potentially limited the district court’s claim construction of
claim thirteen so as to make the record incomplete for purposes
of assessing whether claim thirteen recited patentable subject

39. Transcript of Oral Argument, Lab. Corp. of Am. Holdings v.
Metabolite Labs., 126 S. Ct. 2921 (2006) (No. 04-607), available at
http://www.supremecourtus.gov/oral_arguments/argument_transcripts/04607.pdf. The Supreme Court spent a significant amount of time at oral
arguments trying to determine whether Petitioner’s § 112 arguments, which
were pled and argued in the lower courts, legitimately incorporated the issue
before the Court, namely whether claim thirteen recited patentable subject
matter. Id.
40. Brief for the United States as Amicus Curiae, supra note 36; Brief for
the Respondents, supra note 23, at 19. LabCorp argued, as affirmative
defenses, that claim thirteen was invalid, unenforceable and/or void for
lacking novelty, nonobviousness, definiteness, lacking an adequate written
description and being insufficiently enabling. Id. at 8.
41. Id.
42. Id. at 8–9.
43. Id. at 10.
44. Brief for Respondents, supra note 23, at 20–26.
45. Brief for the United States as Amicus Curiae, supra note 40, at 5.
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matter. 46
Further, the Solicitor General noted that the Federal
Circuit has interpreted the Court’s holding in Diehr to
substantially limit its holding in Flook, so that what would
have been unpatentable subject matter under Flook because all
that was recited was a mathematical formula, is now
patentable under Diehr as long as the claim containing the
formula implements a process that taken as a whole performs a
useful function. The Solicitor General stated that the PTO had
issued “numerous” patents based on the Federal Circuit’s
interpretation of those cases. 47 The Solicitor General cautioned
that overturning the PTO’s approach to patentable subject
matter could “call into question a substantial number of patent
claims and undermine the settled expectations of numerous
participants in technology-based industries.” 48 The Solicitor
General argued that this was an inappropriate case for
“examining such a fundamentally important issue,” because the
issue was not litigated below, and consequently the record was
incomplete on the issue. 49
THE DISSENT
Justice Breyer, joined by Justices Stevens and Souter,
dissented from the Court’s dismissal of the writ. 50 Justice
Breyer would have found claim thirteen invalid because it does
not claim patentable subject matter, but rather attempts to
claim a natural phenomenon, which is impermissible. 51 He
argued that the Court should have decided the case because the
Court had the authority to decide the issue, which was not
“unusually difficult”, and that “those who engage in medical
research, who practice medicine, and who as patients depend
upon proper health care, might well benefit from this Court’s

46. Id. at 9–16. The district court, had it known § 101 was at issue, may
have required that the parties provide more information so it could determine
whether or not the claim term “assay” could mean that assaying bodily fluid
necessarily involves the transformation of matter from one state to a different
state, and if “assay” could be so construed, that would weigh heavily in favor of
claim thirteen reciting patentable subject matter under the Federal Circuit’s
interpretation of Benson, 409 U.S. 63, and Diehr, 450 U.S. 175.
47. Id. at 13–14.
48. Id. at 14.
49. Id. at 14–15.
50. Lab. Corp. of Am. Holdings v. Metabolite Labs.,126 S. Ct. at 2921.
51. Id. at 2927.
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authoritative answer.” 52
The dissent agreed with LabCorp’s argument that LabCorp
did present the issue of subject matter to the Federal Circuit,
because subject matter was necessarily incorporated in its §
112 invalidity arguments. 53 Because the heart of the argument
was presented below he found the procedural reason for
Justice Breyer
dismissing the result “tenuous.” 54
acknowledged that the Federal Circuit’s specific review of the
issue would have been helpful but that the case should have
been decided anyway because it was fully briefed by the parties
and many amici, and the record was thorough and complete. 55
Finally, he argued that he believed the “important
considerations of the public interest – including that of
clarifying the law in this area sooner rather than later” was a
significant reason to decide the issue and not dismiss the
writ. 56
While admitting that the law surrounding the exceptions
to patentable subject matter “is not easy to define,” he
concluded that the process described in claim thirteen was an
easy case, and did not require a complex interpretation of the
natural phenomenon line of cases. 57 Clearly, he argued, the
correlation between elevated homocysteine levels and a
deficiency in one or both of the B vitamins (folic acid and B12)
He rejected Metabolite’s
was a natural phenomenon. 58
argument that it patented a process that included transforming
matter from one state to another, because claim thirteen did
not claim the assaying step. 59 In fact, claim thirteen claimed
any method of assaying for total homocysteine levels, whether
that method was patented, unpatented, or not yet invented. 60
Claim thirteen did not cover the method for testing itself, thus,
the fact that the method for testing might transform bodily
fluid from one state to another cannot save claim thirteen from

52.
53.
54.
55.
56.
57.
58.
59.
60.

Id. at 2922.
Id. at 2925–6.
Id. at 2925.
Id. at 2926.
Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. at 2926.
Id. at 2926–27.
Id. at 2927.
Id.
Id.
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reciting unpatentable subject matter. 61
Justice Breyer also rejected Metabolite’s argument that
claim thirteen recited a useful, concrete and tangible result,
which the Federal Circuit held adequate to save a claim from
subject matter invalidity in State Street Bank & Trust v.
Significantly, Justice
Signature Financial Group, Inc.. 62
Breyer acknowledged that the case stood for that proposition,
but that “this Court has never made such a statement and, if
taken literally, the statement would cover instances where this
Court has held the contrary.” 63
Even so, assuming arguendo that claim thirteen met
general requirements for process patentability, Justice Breyer
stated that the claim would still be invalid because it is simply
nothing more than “the natural law at issue in the abstract
patent language of a ‘process.’” 64 Justice Breyer concluded the
dissent by stating that if he was correct in finding claim
thirteen unpatentable, then the medical community and
patients are threatened by permitting the claim to stand. 65 He
continued to state that if he was not correct that claim thirteen
is unpatentable, then the medical community would still be
aided by clarifying confusion in this area of law, “diminish[ing]
legal uncertainty in the area” that could potentially affect a
significant number of existing patents, and providing Congress
with the knowledge needed to determine whether further
legislation would be required. 66
SOME OF THE CONCERNS
The Supreme Court’s grant of certiorari to consider subject
matter patentability in this case had some anxious and others
optimistic. For instance in the amicus brief filed by the Federal
Circuit Bar Association (FCBA) in support of respondents,
FCBA argued that according to the Federal Circuit few cases
fall into the judicially created exceptions to § 101 (laws of
nature, natural phenomena, and abstract ideas) largely
because those exceptions have been difficult to apply to specific
61. Lab. Corp. of Am. Holdings v. Metabolite Labs, 126 S. Ct. at 2927–8.
62. Lab. Corp. of Am. Holdings v. Metabolite Labs., 126 S. Ct. at 2928
(citing to State St. Bank & Trust v. Signature Fin. Group, Inc., 149 F.3d 1368,
1373 (Fed. Cir. 1998)).
63. Id.
64. Id.
65. Id. at 2928–9.
66. Id. at 2929.
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cases. 67 The FCBA argued that “history shows that judicial
exceptions to § 101 tend to create more problems than they
solve. 68 If “Congress deemed it necessary, it could amend §
101, but it has left the scope of § 101 unaltered
notwithstanding a debate that is far older than the statute
itself.” 69 The FCBA believes the Federal Circuit’s holding in
this case should stand, and further that the Federal Circuit’s
precedent in this area should not be disturbed. 70
Conversely, in an amicus brief filed by Financial Services
Industry (FSI) in support of reversal, FSI argued that the
Federal Circuit had “effectively nullified” the Supreme Court’s
“reservation of abstract ideas to the public domain – and
attracted significant academic criticism in the process.” 71 FSI
argued that clearly unpatentable claims under a “commonsense” reading of the Court’s holding in Diehr could now be
easily patented under the Federal Circuit’s current
interpretation of § 101. 72 FSI argued that allowing claim
thirteen to stand would mean “the free-for-all in the patenting
of abstract business methods would continue and undoubtedly
hinder innovation and efficiency in the financial services
industry for decades.” 73 More generally, it warned that the
Court’s decision in this case could have “significant economic
repercussions.” 74
American Clinical Laboratory Association (ACLA) argued
in its amicus brief in support of petitioner that if the Court
found claim thirteen valid it would mean “any researcher who
discovers a chemical association in the human body will be able
to claim a monopoly over any future diagnostic test based on
that association.” 75 ACLA stated that this prohibition would

67. Amicus Curiae Brief of the Federal Circuit Bar Association in Support
of Respondents at 15, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-607), 2006 WL 303906.
68. Id.
69. Id.
70. Id.
71. Brief of Financial Services Industry Amici Curiae in Support of
Reversal at 9, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-607), 2005 WL 3543097.
72. Id.
73. Id. at 1.
74. Id.
75. Brief of the American Clinical Laboratory Association as Amicus
Curiae in Support of Petitioner at 1-2, Lab. Corp. of Am. Holdings v.
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either entirely preclude further innovation and improvements
in diagnostic tests that are based upon a patented correlation,
or that further innovation and improvement, if they do occur at
all, will only occur at a “higher price and on a limited basis.” It
continued that “either way, laboratories’ ability to provide new
lifesaving tests and patients’ access to those tests would
suffer.” 76
On the other hand, Perlegen Sciences, Inc. 77 (Perlegen) and
Mohr, Davidow Ventures 78 (MDV) argued in their amicus brief
in support of respondents that economic and scientific
considerations argue in favor of upholding the Federal Circuit
and PTO’s current subject matter interpretation, and that
claim thirteen should be held to recite patentable subject
matter. 79 It argued that a holding that claim thirteen did not
recite patentable subject matter “could significantly diminish
Perlegen’s incentive to engage in research and to develop
diagnostic methods for determining the patient population for
which particular drugs are safe and effective.” 80 MDV argued
that it provided funding to diagnostic start-ups knowing that
processes such as those recited in claim thirteen “have been
consistently granted patent protection over an extended period
of time.” 81 MDV stated that if claim thirteen, and those like it,
is found invalid it “could limit the economic viability of
companies seeking to research and develop diagnostic methods
like that identified in Claim 13 . . . .” 82 MDV concluded that
venture capitalists “would have significantly diminished
incentives to invest in the very companies that are on the
forefront of research and development in personalized medicine
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607), 2005 WL 3543098.
76. Id. at 2.
77. Perlegen is “a leader in personalized medicine, working to provide safe
and effective medications to patients worldwide.” Brief for Amici Curiae
Perlegen Sciences, Inc., and Mohr Davidow Ventures in Support of
Respondents at 1, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-607), 2006 WL 303908.
78. MVD is a “leading Silicon Valley-based venture capital firm
specializing in predictive diagnostics and personalized medicine.” Id. at 2.
MDV works with academic institutions that invent and commercialize novel
technologies and business models helping to build start-ups. Id.
79. Brief for Amici Curiae Perlegen Sciences, Inc., and Mohr, Davidow
Ventures in Support of Respondents, supra note 77, at 1.
80. Id. at 1–2.
81. Id.
82. Brief for Amici Curiae Perlegen Sciences, Inc., and Mohr, Davidow
Ventures in Support of Respondents, supra note 77, at 2.
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and diagnostics.” 83
CONCLUSION
There are many concerns about the doctrine of patentable
subject matter, with the above concerns only presenting a
sample of the potential issues that will face the Court should it
decide to take up this issue in the near future. The mere fact
that the Court granted cert on this issue after a quarter
century of silence on the matter would seem to indicate the
Court believes the issue needs to be altered, or at lease
clarified. The fervent dissent of three Justices, the only ones to
discuss the issue on its merits, is also telling of where the Court
may go with the issue.
The evolution of science and technology has forced the
Court to look at subject matter anew in the past. More than
twenty-five years have passed since the doctrine has been
revisited by the Court, and we find ourselves facing
dramatically
different
scientific
and
technological
advancements, which could not have been appreciated when
Diehr was decided. Regardless of what the Court decides when
it takes the matter up again, all will benefit from more
certainty in the area of what constitutes patentable subject
matter.

83. Id. at 3.

